Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Cell Cycle Année : 2019

Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity

Résumé

Senescence is activated in response to chemotherapy to prevent the propagation of cancer cells. In transformed cells, recent studies have shown that this response is not always definitive and that persistent populations can use senescence as an adaptive pathway to restart proliferation and become more aggressive. Here we discuss the results showing that an incomplete and heterogeneous senes-cence response plays a key role in chemotherapy resistance. Surviving to successive chemotherapy regimens, chronically existing senescent cells can create a survival niche through paracrine cooperations with neighboring cells. This favors chemotherapy escape of premalignant clones but might also allow the survival of adjacent clones presenting a lower fitness. A better characterization of senescence heterogeneity in transformed cells is therefore necessary. This will help us to understand this incomplete response to therapy and how it could generate clones with increased tumor capacity leading to disease relapse. ARTICLE HISTORY

Domaines

Cancer
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02281354 , version 1 (09-09-2019)

Identifiants

Citer

Jordan Guillon, Coralie Petit, Bertrand Toutain, Catherine Guette, Eric Lelievre, et al.. Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity. Cell Cycle, 2019, 18 (19), pp.2385-2397. ⟨10.1080/15384101.2019.1652047⟩. ⟨inserm-02281354⟩
95 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More